Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
Research and development expenses, net $ 4,097 $ 2,864 $ 8,005 $ 5,600
General and administrative expenses 2,297 1,203 4,355 2,190
Operating loss 6,394 4,067 12,360 7,790
Financial income, net (188) (289) (253) (787)
Net Loss $ 6,206 $ 3,778 $ 12,107 $ 7,003
Basic and diluted loss per share of Common Stock $ 0.27 $ 2.50 $ 0.53 $ 4.68
Weighted average number of shares of Common Stock outstanding, basic and diluted 22,969,075 2,005,047 22,944,482 2,005,047